A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

This trial tests a new targeted therapy drug called HS-10504 in people with advanced or spreading non-small cell lung cancer (NSCLC) whose tumors carry an EGFR mutation and whose cancer has progressed after previous EGFR-targeted treatment. **You may be eligible if...** - You are 18 or older with confirmed advanced or metastatic NSCLC - Your tumor has an EGFR mutation confirmed by testing - Your cancer has progressed on or after previous EGFR-targeted therapy (EGFR-TKIs) - You have at least one measurable tumor on scans - You are in good health with a life expectancy over 12 weeks **You may NOT be eligible if...** - Your cancer has other known driver mutations besides EGFR - You have had a fourth-generation EGFR inhibitor previously - You have had chemotherapy or other anti-cancer drugs within 14 days of starting the study - You have received recent radiation therapy Talk to your doctor to see if this trial is right for you.